• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Dr David Tuller: More Disinformation from Professor White in Journal of Psychosomatic Research

Countrygirl

Senior Member
Messages
5,505
Location
UK
https://www.virology.ws/2021/06/10/...Sf4APufpdbiTLXrwKf1tZrt5WKhcnQMN7vAUaCihM_1J4


Trial By Error: More Disinformation from Professor White in Journal of Psychosomatic Research
10 June 2021 by David Tuller 1 Comment
By David Tuller, DrPH

The Journal of Psychosomatic Research seems to be suffering from some sort of identity crisis. Earlier this year, the editor and his two immediate predecessors published an admirable editorial in which they noted the serious risk of bias in subjective outcomes in studies that are not rigorously blinded. Yet the journal’s editorial advisory board is studded with investigators who specialize in unblinded studies that rely solely on subjective outcomes—in particular, Professors Peter White and Michael Sharpe, two of the lead PACE investigators, and Professor Per Fink, their Danish colleague.

And the journal keeps publishing studies based on such flawed research, in the process undermining its own credibility and raising questions about whether its editorial team is actually in charge of editorial policy. How else to explain the recent paper from Professor White and colleagues of one-year follow-up results from GETSET, a study of self-guided graded exercise therapy (GET) for the illness they call chronic fatigue syndrome (CFS)? This follow-up managed to present null results at one year as a success by engaging in blatant outcome-switching.
How exactly did the authors accomplish this feat? They prioritized a “within-group” comparison for the GETSET arm as the most important result rather than the “between-group” comparison that is the outcome of interest in any clinical trial. In other words, they highlighted first and foremost the fact that the purported early benefits from GETSET were maintained at follow-up rather than the most salient detail–that in the end there were no demonstrable differences between the intervention and comparison arms..........